| Date | Title | Description |
| 15.04.2025 | Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets ... |
| 23.06.2022 | Syros Pharmaceuticals Implements Genedata Profiler to Accelerate Therapeutic Development for Genomically Targeted Patient Populations | “Genedata Profiler’s unique approach has the capacity to provide state of the art data integration and analytics. This partnership allows us to leverage Genedata’s expertise to help us bring our drugs to the right patients.” Nancy Simonian,... |
| 07.12.2020 | Ally Bridge Portfolio News – Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies | Oral Arsenic Trioxide has Potential to Reduce Treatment Burden of Standard-of-Care Regimen that Cures Most Patients
Dose Confirmation Study Expected to Begin in Second Half of 2021, Followed by Registration-Enabling Phase 3 Trial in 2022
... |
| 17.10.2019 | PhI fizzle forces Syros to spike its lead drug, triggering another rout on shares | Less than stellar Phase I results have triggered a pipeline cleanup at Syros Pharma, where one of its two lead drugs — a CDK7 inhibitor administered intravenously — is getting swapped out with an oral version.
The biotech said... |
| 17.10.2019 | Syros eyes strategic shift after failure of hitherto promising cancer drug | Shares of Syros were down 32.3 percent on the Nasdaq following the news.
The company has consequently decided to shift its focus from SY-1365 to another drug, the oral CDK7 inhibitor SY-5609, which it said inhibits CDK7 more selectively and... |
| 26.04.2017 | Syros Closes $35 Million Private Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced today that it has closed... |
| 15.01.2016 | Syros raises $40M to get its leukemia drug into Phase II | Syros CEO Dr. Nancy Simonian
Syros Pharmaceuticals raised $40 million in equity to push forward with its pipeline of genetically targeted drugs, securing the cash it needs to take its top prospect into Phase II.
New investor Deerfield Manag... |
| 13.01.2016 | Syros Pharmaceuticals Closes $40M Financing Round | Syros Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company that develops medicines that control the expression of genes, closed a $40m financing round.
The round was led by new investor Deerfield Management Company with parti... |
| 13.01.2016 | Syros Pharmaceuticals Lands $40M |
CAMBRIDGE, MA, Syros Pharmaceuticals today announced the closing of a $40 million financing of preferred stock.
>> Click here for more funding data on Syros Pharmaceuticals
>> To export Syros Pharmaceuticals funding data to ... |
| 13.01.2016 | Daily funding roundup - January 13, 2016 | Zerto secured $50M; Syros Pharmaceuticals closed $40M financing; Shape Security raised $25M funding
Bolste, provider of a business collaboration platform, announced today that it is launching its business operating system (BOS) one month af... |
| 12.01.2016 | Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing | – Company Advancing Pipeline of Clinical and Preclinical Product Candidates and Proprietary Gene Control Platform –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals today announced the closing of a $40 million financing of preferred ... |
| 31.10.2014 | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | $33 million in equity raised, closing out a $48 million Series E round
The funding will bring Aileron candidate ALRN-6924 – a drug that works to activate a solid tumor suppressor protein called p53 – to clinical trial. The company says its ... |
| 27.10.2014 | Syros Pharmaceuticals Closes $53 Million Series B Financing | WATERTOWN, MA, October 27, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has closed its Series B round with $53 ... |
| 27.10.2014 | Syros Raises $53M More To Push Gene-Control Drugs Into Human Trials | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The backers of Syros Pharmaceuticals are sparing no expense. The Watertown, MA-based biotech has reeled in a $53 million Series B round, a huge sum for a company based on rela... |
| 27.10.2014 | A whopping $53.1M Series B will help Syros Pharmaceuticals advance toward clinic for cancer | “Precise control of genes is at the heart of cell identity and function,” the company says. “When gene control is fundamentally altered or lost, healthy, normal cells transform into diseased cells – in essence, disease is caused by cell mis... |
| 27.10.2014 | Syros Pharmaceuticals Closes $53M Series B Funding | Syros Pharmaceuticals, a Watertown, MA-based therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, closed a $53m Series B funding.
The round was led by a large, Boston-based pu... |
| 27.10.2014 | Syros Pharmaceuticals Closes $53M Series B |
WATERTOWN, MA, Therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has closed its Series B round.
>> Click here for more funding data on Syro... |
| 12.04.2013 | Syros Pharmaceuticals Completes $30M Series A Financing | Syros Pharmaceuticals, a Watertown, MA-based life sciences company that leverages discovers in gene control to innovate the treatment of cancer and other diseases, completed a $30m Series A financing.
The round was led by ARCH Venture Partn... |
| 11.04.2013 | Syros Pharma Launches with $30M Series A |
WATERTOWN, MA, Newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, today announced that it has completed a $30 million Series A financing.
>> Click here for m... |
| 11.04.2013 | Pharma startup gets $30M for genetic cancer treatments | Syros Pharmaceuticals, a company that aims to revolutionize the treatment of cancer and other diseases, announced today it has raised $30 million in financing from Flagship Ventures and ARCH Venture Partners.
This is the company’s first rou... |
| 11.04.2013 | Pharma startup gets $30M for genetic cancer treatments | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Syros Pharmaceuticals, a company that aims to rev... |
| 11.04.2013 | Funding Daily: Peanut butter and banana sandwiches | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Today’s funding daily is dedicated to peanut butt... |
| 11.04.2013 | Funding Daily: Peanut butter and banana sandwiches | Today’s funding daily is dedicated to peanut butter and banana sandwiches. Why? Because a startup that delivers homemade, organic, peanut butter and banana sandwiches to your door raised money. Not really. Rather, it is because this unfortu... |
| 11.04.2013 | Syros Pharma snags $30M funding deal to target master switches of cancer genes | With licenses to breaking discoveries from labs affiliated with MIT and Harvard, Syros Pharmaceuticals has raised $30 million in a Series A round of financing from top venture firms. And after operating under the radar, the biotech startup ... |
| - | Syros eyes strategic shift after failure of hitherto promising cancer drug | A biotech company developing drugs that treat cancers by controlling gene expression is shifting its focus following the failure of a drug that it was testing in patients with solid tumors.
Cambridge, Massachusetts-based Syros said Thursday... |
| - | A whopping $53.1M Series B will help Syros Pharmaceuticals advance toward clinic for cancer | Gene regulation startup Syros Pharmaceuticals has raised a $53.1 million from 16 investors, according to regulatory filings.
This financing round was led by “a large, Boston-based public investment firm,” also includes new investors Polaris... |
| - | Funding Roundup: Which biotech, medtech and healthIT startups got investments this week? | Each week, many millions are invested into life sciences startups. There are so many that often, they get lost in the weeds. We’re keeping track for you – based on regulatory filings reported to the SEC. Here are the new funding notices fro... |
